Delving into the Latest Updates on CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd. with Synapse

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection in the Prevention of Post-operative Nausea and Vomiting

A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,

开始日期2024-10-28

申办/合作机构

CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

NCT06621199 / Recruiting临床2期IIT

A Prospective, Single-arm, Multi-center, Phase 2 Clinical Study of Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

This is a phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome in combination with cytarabine and venetoclax (MAV) regimen in newly diagnosed elderly AML. To account, conservatively, for a 10% dropout rate before study completion, we planned to include 42 patients. The primary endpoint is 2-year event free survival(EFS).

开始日期2024-07-08

申办/合作机构

The First Affiliated Hospital, Zhejiang University School of Medicine

[+1]

NCT06621212 / RecruitingN/AIIT

A Prospective, Single-center, Exploratory Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Standard-dose Cytarabine and Venetoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

The purpose of this prospective, single-center, single-arm, exploratory study is to evaluate the efficacy and safety of a combination regimen of mitoxantrone hydrochloride liposome injection, standard-dose of cytarabine and venetoclax (MAV) in the treatment of relapsed or refractory (R/R) AML. The study plan to enroll 20 R/R AML patients who are expected to receive laboratory tests of bone marrow and blood specimens at regular times after MAV treatment.

开始日期2024-07-05

申办/合作机构

The First Affiliated Hospital, Zhejiang University School of Medicine

[+1]

100 项与 CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd. 相关的临床结果

登录后查看更多信息

0 项与 CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd. 相关的专利（医药）

登录后查看更多信息

4

项与 CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd. 相关的文献（医药）

2015-01-01·Evidence-Based Complementary and Alternative Medicine4区 · 医学

Neuroprotective Effect of Xueshuantong for Injection (Lyophilized) in Transient and Permanent Rat Cerebral Ischemia Model

4区 · 医学

ArticleOA

作者: Chai, Lijuan ; Wang, Jinxin ; Wang, Xumei ; Zhang, Yue ; Chen, Lu ; Wang, Shaoxia ; Guo, Hong ; Wang, Hong ; Hu, Limin ; Dong, Zhaopeng

Xueshuantong for Injection (Lyophilized) (XST), a Chinese Materia Medica standardized product extracted fromPanax notoginseng(Burk.), is used extensively for the treatment of cerebrovascular diseases such as acutely cerebral infarction clinically in China. In the present study, we evaluated the acute and extended protective effects of XST in different rat cerebral ischemic model and explored its effect on peroxiredoxin (Prx) 6-toll-like receptor (TLR) 4 signaling pathway. We found that XST treatment for 3 days could significantly inhibit transient middle cerebral artery occlusion (MCAO) induced infarct volume and swelling percent and regulate the mRNA expression of interleukin-1β(IL-1β), IL-17, IL-23p19, tumor necrosis factor-α(TNFα), and inducible nitric oxide synthase (iNOS) in brain. Further study demonstrated that treatment with XST suppressed the protein expression of peroxiredoxin (Prx) 6-toll-like receptor (TLR) 4 and phosphorylation level of p38 and upregulated the phosphorylation level of STAT3. In permanent MCAO rats, XST could reduce the infarct volume and swelling percent. Moreover, our results revealed that XST treatment could increase the rats’ weight and improve a batch of functional outcomes. In conclusion, the present data suggested that XST could protect against ischemia injury in transient and permanent MCAO rats, which might be related to Prx6-TLR4 pathway.

Hebei Yike Daxue Xuebao

Prescription process and preparation methods of non bitterness roxithromycin dispersible tablets

作者: Zhao, Zhenkun ; Han, Qiaoling ; Xu, Lingyun ; Zhang, Li

Prescription process and preparation methods of non bitterness roxithromycin dispersible tablets were discussed.Influence of lactose, mannitol, microcrystalline cellulose, crospovidone, microcrystalline cellulose and sodium CM-cellulose composites, pre-gelatinized starch, sodium carboxymethyl starch, aspartame, orange flavor and other accessories on quality of roxithromycin dispersible tablets was discussed, disintegrants, fillers, flavoring agents, suspending agents were optimized.Influence of chosen accessories on quality of roxithromycin dispersible tablets (taste, disintegration, dispersion uniformity, sedimentation volume ratio, etc.) by direct pressure powder, dry granulation method and wet granulation tabulating was observed to find finial preparation process.Best prescription was optimized by orthogonal design and 3 batches of pilot scale test were applied.By optimization of disintegrants, fillers, flavoring agents, suspending agents and preparation and combined with orthogonal design, best prescription of non bitterness roxithromycin dispersible tablets was determinedThe process was simple, cheap and safe, and it had broad prospects in market.

Anhui Nongye Kexue

Study on the preparation of baicalin sustained-release microcapsule

作者: Yue, Hong-kun ; Qi, Lei ; Chang, Ming ; Wang, Yu-mei ; Zhang, Jing

To prepare sustained-release microcapsules of baicalin, design and optimize the prescription, and make initial quality standards of this preparationA complex coacervation method was applied to prepare sustained-release microcapsules using gelatin and gum arabic as wall materials, baicalin capsule as core and Tween-80 as the wetting agent.Taking the encapsulation rate as main quality indicators, the preparation process of microcapsules was optimized by single factor experiment and orthogonal test.Microencapsulated form was observed using microscopy and electron microscopy; content was determined by UV spectrophotometry; the in vitro dissolution of preparation was investigated using water as dissolution medium.The optimum prescription process was: gelatin concentration of 13.3 mg/mL, gum arabic of 13.3 mg/mL, reaction temperature of 50°, pH value of 3.90 and drug material ratio of 5:1.The microcapsules of baicalin prepared under the above prescription were capsule-shaped and round smooth and of high drug loading.The baicalin microcapsules with high encapsulation rate could be successfully prepared by complex coacervation method, and the product had good stability.This method was feasible, reproducible, and of some practical value.

100 项与 CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd. 相关的药物交易

登录后查看更多信息

100 项与 CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd. 相关的转化医学

登录后查看更多信息